Abstract: Provided are an ovary-targeting polypeptide, a derivative of the polypeptide, and the use of the polypeptide in the preparation of a drug or reagent for treating ovarian related reproductive diseases and preventing and treating the in-vivo or in-vitro aging of oocytes. The diseases comprise menstrual cycle disorder, polycystic ovary syndrome, androgenic phenotype, hair loss, abnormal metabolism, ovarian insufficiency, premature ovarian failure, ovulation failure, abnormal glucose metabolism, and abnormal lipid metabolism, preferably, hyperglycemia and insulin resistance. In addition, the polypeptide is expected to prolong the preservation time and improve the preservation quality of oocytes or fertilized eggs in the field of assisted reproduction.

Abstract: A peptide for regulating fat metabolism is described. The peptide is selected from the group consisting of: YLGASVPSPDPLEP (SEQ ID NO: 1); YLNNGLGAPAPYPDPLEP (SEQ ID NO: 4); PDPLEP (SEQ ID NO: 14); and PSPDPLEP (SEQ ID NO: 16).

Abstract: The present disclosure relates to a peptide for regulating fat metabolism and a method of regulating fat metabolism in an individual. The peptide is a variant of a SEQ ID NO: 2 having an amino acid sequence of YLYQWLGAPVPYPDPLEP, the variant comprises peptides selected from the group consisting of: (a) a first amino acid sequence consisting of the SEQ ID NO: 2, no more than 5 amino acids inserted to a C-terminal of the SEQ ID NO: 2, and no more than 5 amino acids inserted to a N-terminal of the SEQ ID NO: 2; (b) a second amino acid sequence consisting of a modified SEQ ID NO: 2; and (c) a third amino acid sequence consisting of at least 6 contiguous amino acids of the SEQ ID NO: 2 or the modified SEQ ID NO: 2.

Abstract: Peptide that regulates fat metabolism and is used in the preparation of a medicament for the treatment of diseases associated with abnormalities in energy metabolism is described, particularly fat metabolism. The peptide of the present disclosure can reduce fat absorption, reduce fat accumulation in the liver and regulate fat metabolism, and has an advantage of being orally administered as compared with other general peptide products, and thus can also be used as an active ingredient of a health care product for regulating fat metabolism.

Abstract: The present disclosure relates to a peptide that regulates fat metabolism and uses thereof in the preparation of a medicament for the treatment of diseases associated with abnormalities in energy metabolism, particularly fat metabolism. The peptide of the present disclosure can reduce fat absorption, reduce fat accumulation in the liver and regulate fat metabolism, and has an advantage of being orally administered as compared with other general peptide products, and thus can also be used as an active ingredient of a health care product for regulating fat metabolism.